Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical…
Month: August 2021
Voyager Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene…
Codex DNA Reports Second Quarter 2021 Financial Results
SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer…
Acer Therapeutics Reports Q2 2021 Financial Results and Provides Corporate Update
NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical…
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
ORIC-101 on track for initial Phase 1b data readout in prostate cancer in 2H21 ORIC-533…
Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights
– Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022- –…
Day One Reports Second Quarter 2021 Financial Results and Corporate Progress
DAY101 Granted Rare Pediatric Disease Designation from FDA DAY101 Granted Orphan Designation from European Commission…
Akoya Reports 53% Revenue Growth in the Second Quarter of 2021
MARLBOROUGH, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The…
Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2022
U.S. FDA reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension…
Clearside Biomedical Announces Second Quarter 2021 Financial Results and Provides Corporate Update
– Enrollment Underway in Cohort 2 of OASIS Wet AMD Phase 1/2a Trial with Data Expected…
Talis Biomedical Announces Second Quarter 2021 Financial Results and Business Progress
Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific MENLO PARK, Calif., Aug. 10, 2021…
Zosano Pharma Reports Second Quarter 2021 Financial Results
FREMONT, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company,…
Bioventus Reports Second Quarter Results; Updates Full Year 2021 Financial Guidance
DURHAM, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update
Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Aug….
Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
– Commenced dosing in Phase 3 PATHFNDR-1 study – – Phase 1 single-ascending dose data…
CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity
CB4211 was well-tolerated and appeared safe with no serious adverse events Robust reductions in ALT…
Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September Approximately $218…
POINT Biopharma Announces Early Completion of enrollment and initial dosing in the Lead-In of its Phase 3 SPLASH study of PNT2002 for mCRPC
INDIANAPOLIS, Aug. 10, 2021 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT), a company…
Applied Molecular Transport Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Top-line data readouts expected from four Phase 2 trials of oral AMT-101, consistent with previous…
Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study
CRN04894 Phase 1 Study Progressing to Multiple Ascending Dose Cohorts Management Hosting Webcast and Conference…